SCHEMBL5129657

SCHEMBL5129657

COC(=O)CCc1cnc(C(C)OCc2ccc(OC)cc2)s1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
ALDH1A1 P00352 3/20 0.40
FFAR1 O14842 2/20 0.40
ABL1 P00519 1/20 0.39
ADRB2 P07550 1/20 0.39
ADRB1 P08588 1/20 0.39
GAA P10253 2/20 0.39
MAPT P10636 2/20 0.39
F2RL1 P55085 1/20 0.39
VDR P11473 1/20 0.38
PPARD Q03181 1/20 0.38
TP53 P04637 1/20 0.38
SIRT2 Q8IXJ6 1/20 0.38
POLB P06746 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
TBXAS1 P24557 1/20 0.37
LMNA P02545 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12868678 0.80 RPS6KB2 (0.41) ALDH1A1ADRB2ADRB1MAPTTP53
SCHEMBL5128640 0.76 RPS6KB2 (0.40) CYP11B1CYP11B2ALDH1A1ADRB2ADRB1
SCHEMBL6180184 0.69 CTSK (0.49)
SCHEMBL1445627 0.69 F2RL1 (0.73) CYP11B1CYP11B2ALDH1A1FFAR1MAPT
SCHEMBL10220130 0.69 POLB (0.64) ALDH1A1ABL1SIRT2POLBMEN1
SCHEMBL4008532 0.69 RPS6KB2 (0.43) CYP11B1CYP11B2ALDH1A1FFAR1GAA
SCHEMBL15825442 0.67 RPS6KB2 (0.44) CYP11B1CYP11B2ALDH1A1GAAMAPT
SCHEMBL10289763 0.67 RPS6KB2 (0.44) CYP11B1CYP11B2ALDH1A1FFAR1GAA
SCHEMBL4594749 0.66 SMN1; SMN2 (0.55) ALDH1A1MAPTPOLBTDP1L3MBTL1
SCHEMBL18574128 0.66 ALDH1A1 (0.44) ALDH1A1MAPTTP53MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080108675-A1 THIAZOLE SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER INC. 2008-05-08 US disclosed
US-7309709-B2 Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders PFIZER INC. (US) 2007-12-18 US disclosed
US-20050222223-A1 Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders PFIZER INC. 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222223-A1 Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders APP, PSEN1, PSEN2 CYP11B1 2180/4885CYP11B2 2562/4885ALDH1A1 1228/4885
US-20080108675-A1 THIAZOLE SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS APP, PSEN1, PSEN2 CYP11B1 2180/4885CYP11B2 2562/4885ALDH1A1 1228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.